{"id":597009,"date":"2026-02-17T19:31:15","date_gmt":"2026-02-17T19:31:15","guid":{"rendered":"https:\/\/www.europesays.com\/us\/597009\/"},"modified":"2026-02-17T19:31:15","modified_gmt":"2026-02-17T19:31:15","slug":"compass-pathways-soars-as-psilocybin-depression-treatment-hits-second-phase-3-trial-goals-endpoints-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/597009\/","title":{"rendered":"Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals &#8211; Endpoints News"},"content":{"rendered":"<ol>\n<li><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMihgFBVV95cUxQMndIc0FTREhBcXZ2c2UwbUo2WTNFZnNCaVdTRnc1TGFHTlpyQ21Yc1FKVlJGOHQ5VU50SllwczNfNDB1TVJMOXZ6NDNuVFllMTlKb0tZdF81ZjNZOHAtWFJqRU0zY1BwQ0taYVo0RlFTdUd4dktZVGN2T1B2eWgtZk8zT3ZYQQ?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals<\/a>&nbsp;&nbsp;Endpoints News<\/li>\n<li><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMijgFBVV95cUxNRXZWVlZhWEhHVHp4cHg3ckdSMnJMQ0Z6eUtoR3pESUxVTTlQbkxsQTN0R3AtcllubDdMYmNNUEJlQm1MOXZNc0RkZElzN1A4RlphenBqMVdMUHdFQ0FaNGt6MllBZkZ3cmVwaEFId2pMLVpKRlJnaWNFU0VlVF9UdlJKWFpVMXExX2Z4VTZ3?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials<\/a>&nbsp;&nbsp;Yahoo Finance<\/li>\n<li><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMipwFBVV95cUxQaTJQZHJReFZjUUlrelJBZ2RBSmlmZnFnQTYxZnZJWEktQnZUSndvR2MyTDlnSThRbTVWOFRZTGVLd2kyeVNNdzB0N0s2QkZ0UU1EU3hZMzlBNWZ0YzVnTXV1cGFTalphZERaMU5VRGppRkUtQ0R4S1BvR0FWWHE0NmJFQlBBc1pZN2dBU0dyc2wzR2Rzc1duSGlIZVZHMGVCNFRqS2RyWQ?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Compass says its psilocybin drug helped patients with severe depression in two trials<\/a>&nbsp;&nbsp;statnews.com<\/li>\n<li><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMiwwFBVV95cUxQbHpzY1pCWHJmUEZZZzA2dG82RnZjRlNuTWFXSnh0Z2RXNW41S1dZR3diY3EtdUI5SzJWRGhicld2V3hhMTdjUnF2aWswOVgyNEVLa3hxZFl4MXZKQmVUQWxDbm9nNzJDX0ZkQTlObkJqM0tmRTNJUmIybUtycW1neWZ6TWdGWWRCbXlxWFlzLVpyVktCQ1NjaEl3Q3JjOGFPZGthTmJNLUtyeGxNWU9SYUZhX185VVZqbnItTmpmQ0dReFk?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push<\/a>&nbsp;&nbsp;Fierce Biotech<\/li>\n<li><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMiqAJBVV95cUxNQzEzYjVIX3FyaTFKQnJ5SUVTZkFyWmQ3RjhEOWk3S2dVcDZXOHk4T3M2WHZvMENEUjJpMjBOd0FWcE5YRmtsUjd3ZjNiRDFyd1I1Y0ljV3piY1pQMUFZamx0amhNdkxiV0l4QmtTQjhFc0Rfc01vcTk1NnZ5SWR6MmwxTlYyLU1NN2FXSThpc1Q1c1oyb2p3ZnREc3RlMXNDWDh4UEJrV3p5eERDTklPMF80RGwyZVYzZFdVMnd0NEhOdm41Y0VLX1c4S1JKS3RWcXNqVU5fSS01OGxWbC1aX3lUOTU3Sm5HeTQ0UEd0UU5ZSk5tUjFwcjg5d2VkaHo0OC01ZzBDNlRDa0ZCUFNEaTVtYjFlZGVWYU9HNTRiRXhuQ1BNU0tiQQ?oc=5\" target=\"_blank\" rel=\"nofollow noopener\">Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression<\/a>&nbsp;&nbsp;Business Wire<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals&nbsp;&nbsp;Endpoints News Compass Pathways to Announce&hellip;\n","protected":false},"author":3,"featured_media":597010,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[36],"tags":[3738,257595,25997,210,257597,517,26121,134876,60244,257596,67,132,68],"class_list":["post-597009","post","type-post","status-publish","format-standard","has-post-thumbnail","category-mental-health","tag-clinical-trials","tag-compass-pathways","tag-fda-approval","tag-health","tag-madrs-scale","tag-mental-health","tag-psilocybin","tag-psychiatric-treatment","tag-rd","tag-treatment-resistant-depression","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116087638480090644","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/597009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=597009"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/597009\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/597010"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=597009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=597009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=597009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}